LRIG1 and cancer: The significant reduction in cancer cell viability suggests that LRIG1 reactivation via CRISPR/dCas9 may have an impact on TNBC growth, however, future studies will be required to assess biological relevance in more disease-relevant models such as patient-derived organoids and in vivo mouse models.